Hepion Pharmaceuticals
HEPAHEPA · Stock Price
Historical price data
Overview
Hepion Pharmaceuticals has strategically pivoted to become a pure-play diagnostic company targeting the critical unmet need in early hepatocellular carcinoma (HCC) detection. Its mission is to move from missed diagnoses to timely intervention by commercializing a clinically validated methylated SEPT9 DNA test and developing a next-generation circulating tumor RNA (ctRNA) assay. The company's strategy involves a clear dual-path roadmap: generating near-term revenue via a CLIA laboratory launch while pursuing FDA approval for broader reimbursement and adoption, supported by flexible partnership models for value creation.
Technology Platform
Hepion's platform is built on two complementary liquid biopsy technologies: a clinically validated methylated SEPT9 DNA (mSEPT9) biomarker test for HCC and a next-generation circulating tumor RNA (ctRNA) assay with potential for multi-cancer application.
Pipeline
5| Drug | Indication | Stage | Watch |
|---|---|---|---|
| rencofilstat, 75 mg + rencofilstat, 150mg + rencofilstat, 22... | NASH With Fibrosis | Phase 2 | |
| CRV431 75mg + Placebo (1 softgel) + CRV431 225mg + Placebo (... | NASH - Nonalcoholic Steatohepatitis | Phase 2 | |
| Rencofilstat + Placebo | Nonalcoholic Steatohepatitis (NASH) | Phase 2 | |
| CRV431 + Placebo + TDF | Hepatitis B | Phase 1 | |
| [14C]-rencofilstat 225mg | NASH With Fibrosis | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Hepion competes against the standard of care (ultrasound/AFP), other liquid biopsy companies developing HCC tests (e.g., Freenome, Guardant), and emerging biomarker panels. Its differentiation lies in the clinical validation of its mSEPT9 test for cirrhosis surveillance and its dual DNA+RNA platform strategy.